April / May 2008 - Newsletter
Apr 2008 - NewslettersDownload the file »
TGA statement on Gardasil adverse events
Dec 2007 - News
The Theraputic Goods Administration released a summary of reported adverse events following the distribution of over 2.2 million doses of the human papillomavirus vaccine in Australia.
[This statement has since been updated on the Therapeutic Goods Administration website.]
December 2007 - Newsletter
Dec 2007 - NewslettersDownload the file »
October 2007 - Newsletter
Oct 2007 - NewslettersDownload the file »
SEMINAR: Developing and communicating about immunisation policy - the bit we don't talk about (September 2007)
Sep 2007 - News
This seminar was given by Professor David M Salisbury CB FRCP FRCPCH FFPH, Director of Immunisation, Department of Health, United Kingdom.
The development of immunisation policy in the UK is similar to the model of other industrialised countries: an independent expert advisory committee reviews evidence that it receives, makes recommendations to the Government and these are applied throughout the UK. Where there are differences are in the arrangements for management of the program.
A team of around 20 individuals within the Department of Health manages the strategy development and implementation. Their work spans the bringing together of scientific evidence, the purchase, supply and distribution arrangements for vaccines, the informatics systems for the immunisation program and the communications work that informs and supports immunisation implementation.
The UK program uses the usual process and outcome measurements that are routine (coverage and disease surveillance) but also monitors public knowledge and attitudes about immunisation with equal priority. Given the extent of investment especially in new vaccines, it is of increasing importance that consumer attitudes are monitored and reflected in program management. This aspect of program management requires skills specific to the task and that should be integral within national programs.
Vaccine Preventable Diseases and Vaccination Coverage in Australia, 2003 to 2005
Jun 2007 - News
NCIRS is proud to announce the publication of Vaccine Preventable Diseases and Vaccination Coverage in Australia, 2003 to 2005, which is the fourth national report into Australia’s progress in preventing diseases through vaccination.
The report provides an overview of the 16 diseases preventable by currently available vaccines. These include the 12 for which vaccines were funded nationally for children by the end of 2005 (diphtheria, Haemophilus influenzae type b (Hib) disease, hepatitis B, invasive pneumococcal disease, measles, meningococcal C disease, mumps, pertussis, poliomyelitis, rubella, tetanus and varicella), and another 3 vaccines only funded or recommended for specific high-risk groups (hepatitis A, influenza and Q fever). Rotavirus, for which new vaccines became available in 2006, is also included.
The report can be found at the Communicable Diseases Intelligence website.
April 2007 - Newsletter
Apr 2007 - NewslettersDownload the file »
Communicable Diseases Control Conference (March 2007)
Mar 2007 - News
NCIRS staff presented a number of posters at the CDC conference in Canberra in March 2007. The biennial national conference is held under the auspices of the Communicable Diseases Network Australia and the Public Health Laboratory Network. PDF copies of the posters can be accessed below.
Pandemic influenza: Sydney business leaders discuss the possible impact in a focus group - Ralf Itzwerth
An earlier 2nd dose of MMR? Insights from modelling - James Wood
Pertussis epidemiology in Australia over the decade 1995-2005: trends by region and age group - Helen Quinn
Age-specific trends in varicella hospitalisations in Australia prior to a universally funded program - Anita Heywood
IX International Symposium on Respiratory Viral Infections (March 2007)
Mar 2007 - News
NCIRS staff presented a number of posters at this recent conference in Hong Kong. PDF copies of the posters can be accessed below.
Active surveillance and early intervention with oseltamivir for controlling influenza outbreaks in aged care facilities - Clayton Chiu
An outbreak of influenza B at a chronic care psychogeriatric hospital - Holly Seale
Australian government funds rotavirus vaccine
Mar 2007 - News
Two rotavirus vaccines will be included on the National Immunisation Program, Rotarix from GlaxoSmithKline and RotaTeq from CSL Limited.
The new vaccine will be given orally to babies from 2 to 6 months of age, commencing in July 2007. All babies born from 1 May 2007 will be eligible for the free vaccine. Two or three doses, depending on the brand administered, will generally be given at the same time as other immunisations at around 2, 4 and 6 months of age.
Prev 1 2 3 4 5 6 7 8 9 10 11 12 Next